Coated (e.g., Microcapsules) Patents (Class 424/490)
  • Patent number: 10307511
    Abstract: The present invention generally relates to bioactive composites of polymer and glass and, more particularly, to bioactive implants. The present invention also relates to methods of manufacturing bioactive composites. The bioactive composite finds utility in a variety of load-bearing clinical applications including spine, orthopaedic and dental procedures.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 4, 2019
    Assignee: Orthovita, Inc.
    Inventors: Theodore D. Clineff, Marissa M. Conrad, Matthew B. Havener, James P. Murphy, Zachary S. Szczerbinski
  • Patent number: 10300023
    Abstract: A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 Da), generally regarded as safe (GRAS), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time. The composition is used to deliver one or more therapeutic, prophylactic, or diagnostic agents, allowing for controlled release in response to biological stimuli such as enzymes and a greatly improved dosing efficacy.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 28, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey M. Karp, Nitin Joshi, Nikken Wiradharma, Kai Vincent Slaughter
  • Patent number: 10293056
    Abstract: The present invention relates to non-viral gene therapy methods and compositions for treatment of hyperproliferative disease in humans. More specifically, the invention is directed, in one embodiment, to lipid formulations which form stable liposome structures, capable of efficient in vivo nucleic acid transfer. In other embodiments, methods and compositions are directed to liposome transfer of anti-proliferative nucleic acids, wherein the transfer of the nucleic acids is cell specific via cell specific targeting moieties. The present invention, thus provides non-viral, liposome compositions and methods of gene transfer particularly useful for targeting and treating hyperproliferative disease.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 21, 2019
    Assignees: Board of Regents, The University of Texas System, Introgen Research Institute, Inc.
    Inventors: Rajagopal Ramesh, Jack A. Roth, Tomoyuki Saeki, Deborah R. Wilson
  • Patent number: 10285933
    Abstract: A personal care composition includes an ozone-stressed yeast lysate; and a preservative, in which the preservative is selected from phenoxyethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, butylene glycol, pentylene glycol, methylparaben, propylparaben, butylparaben, benzalkonium chloride, Quaternium 15, methylisothiazolinone, methylchloroisothiazolinone, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, butylated hydroxytoluene, tocopherol, triclosan, chlorohexidine digluconate, and combinations thereof, and the ozone-stressed yeast lysate is produced by a method including exposing growing yeast to ozone by aerating the yeast for a time period of between five minutes and seventy-two hours with an aeration gas having an ozone concentration of from 0.0001 millimolar (mM) to 1.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: May 14, 2019
    Assignee: ARCH PERSONAL CARE PRODUCTS L.P.
    Inventor: James Vincent Gruber
  • Patent number: 10278927
    Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: May 7, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Paula T. Hammond, Zhiyong Poon
  • Patent number: 10251871
    Abstract: Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-?1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 9, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Babak Mehrara, Jason Gardenier, Ira Savetsky, Omer Aras
  • Patent number: 10245322
    Abstract: Methods, systems, and devices are disclosed for fabricating and implementing nanoscale and microscale structured carriers to provide guided, targeted, and on-demand delivery of molecules and biochemical substances for a variety of applications including diagnosis and/or treatment (theranostics) of diseases in humans and animals. In some aspects, a nanostructure carrier can be synthesized in the form of a nanobowl, which may include an actuatable capping particle that can be opened (and in some implementations, closed) on demand. In some aspects, a nanostructure carrier can be synthesized in the form of a hollow porous nanoparticle with a functionalized interior and/or exterior to attach payload substances and substances for magnetically guided delivery and controlled release of substance payloads.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: April 2, 2019
    Assignee: The Regents of the University of California
    Inventors: Ratneshwar Lal, Preston B. Landon, Alexander Mo
  • Patent number: 10247719
    Abstract: Disclosed herein are generally to methods and systems that facilitate imaging of cells on a substrate and more particularly to pre-implantation (in vitro) and post-implantation (in vivo) imaging of cell-seeded substrates implanted in target tissues in the context of stem cell therapy.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: April 2, 2019
    Assignees: UNIVERSITY OF SOUTHERN CALIFORNIA, DOHENY EYE INSTITUTE
    Inventors: Mark Humayun, Ashish Ahuja, Charles Le Pere
  • Patent number: 10233261
    Abstract: A method of making natural polymer (nano)particles, comprises two immiscible phases and a surface active agent, wherein one phase includes a natural polymer source and ionic liquid; stirring the combined phases with surfactant to form a microemulsion; adjusting the ratios of ionic liquid, surfactant, and immiscible phase to determine a particular size of natural polymer nanoparticles; stirring antisolvent into the emulsion; diluting the emulsion; and washing and drying precipitated polymer (nano)particles from the emulsion. The immiscible phase comprises at least one of immiscible solvent, oil, or immiscible ionic liquid. The ionic liquid phase includes natural polymer dissolved in ionic solvent. The antisolvent is water, other protic solvent or additive. The emulsion is diluted with, more immiscible phase, 1-butanol, or a mutually miscible solvent, or oil. The emulsion is diluted with an excess of the volume of the emulsion.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 19, 2019
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jeffrey Alston, Joseph Mabry, Andrew Guenthner
  • Patent number: 10213446
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 26, 2019
    Assignee: BIOrest Ltd.
    Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
  • Patent number: 10203325
    Abstract: The disclosure relates to metal nanoparticle compositions and their methods of formation and use, in particular gold nanoparticles (AuNP) and gold-coated magnetic nanoparticles. Compositions according to the disclosure include aqueous suspensions of metal nanoparticles that are stabilized with one or more carbohydrate capping agents and/or that are functionalized with one or more binding pair members for capture/detection of a target analyte. The nanoparticle suspensions are stable for extended periods and can be functionalized as desired at a later point in time, typically prior to use in an assay for the detection of a target biological analyte. The stable nanoparticle suspension can be formed by the aqueous reduction of oxidized metal precursors at non-acidic pH values in the presence of a carbohydrate-based capping agent such as dextrin or other oligosaccharides.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: February 12, 2019
    Assignee: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Evangelyn C. Alocilja, Hanna Miller
  • Patent number: 10195147
    Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: February 5, 2019
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • Patent number: 10195152
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: February 5, 2019
    Assignee: PURDUE PHARMA L.P.
    Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
  • Patent number: 10195234
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 5, 2019
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • Patent number: 10195228
    Abstract: One aspect of the present invention relates to a multicomponent and biocompatible nanocomposite material, including a graphene structure formed with a plurality of graphene layers; and gold/hydroxyapatite (Au/HA) nanoparticles distributed within the graphene structure; where the nanocomposite material is formed by heating an Au/HA catalyst thin film with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD).
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: February 5, 2019
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Alexandru S. Biris, Alexandru R. Biris
  • Patent number: 10188843
    Abstract: The present disclosure described methods, systems, and techniques for applying contrast-enhanced ultrasound to locate areas of blockage within retinal vessels and to break up clots that are causing damage. In addition to identifying the damaged area, the researchers anticipate that the initial image may serve as a baseline for monitoring the effect of treatment on the vessel, which may be achieved in multiple ways. The vibration effect of the ultrasound itself may suffice to dislodge clots. The microbubbles may also be coated or filled with medication, with ultrasonic shock waves activating the coating or causing mini explosions to release the medicine. Loading the microbubbles with a therapeutic agent, visualizing their presence at the diseased site using the ultrasound diagnostic mode, and then activating the microbubbles to release their contents at the targeted lesion could be a powerful and effective way to reverse occlusion without harming other areas of the eye or body.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: January 29, 2019
    Assignees: UNIVERSITY OF SOUTHERN CALIFORNIA, DOHENY EYE INSTITUTE
    Inventors: Amani Fawzi, Hossein Ameri, Mark S. Humayun
  • Patent number: 10172598
    Abstract: Various embodiments are described herein for a device and method for an ingestible medical device with a rotatable element. In some described embodiments, the ingestible medical device includes a storage sub-unit with multiple chambers each having an opening for collecting or dispensing substances from the GI tract. The device further comprises a chamber enclosure with an access port. One of the chamber enclosure and the storage sub-unit are rotatable to allow for aligning the access port with a chamber opening. The ingestible medical device includes a sensor for positioning the access port of the chamber enclosure or the storage sub-unit as one of these elements rotates.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: January 8, 2019
    Assignee: Progenity, Inc.
    Inventors: Yaw Amoako-Tuffour, Mitchell Jones, Satya Prakash
  • Patent number: 10172805
    Abstract: The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: January 8, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Domenico Fanara, Frédéric Eeckman, Monique Berwaer
  • Patent number: 10149805
    Abstract: The invention describes novel compositions and methods utilized for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include hyperhidrosis, bromhidrosis, and chromhidrosis, One representative composition of the invention comprises; water, alcohol, aluminum sesquichlorohydrate, hydroxypropyl methyl cellulose, polysorbate 20, isopropyl myristate, eucalyptus oil, silicone oil, alkyl benzoate, glycerine, talc, a hydrophillic silica, a hydrophobic silica, phenoxyethanol and ethylhexyl glycerine.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 11, 2018
    Assignee: CLUTCH, INC.
    Inventors: David Bradley Spratte, Jr., Christopher Jenks, Kasper Kubica, Mary Claire Brehm, Shari Deanna Angelina Fonte Clemente
  • Patent number: 10149866
    Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: December 11, 2018
    Assignees: OXTHERA INTELLECTUAL PROPERTY AB, THE MILTON J. ALLISON REVOCABLE TRUST
    Inventors: Harmeet Sidhu, Milton J. Allison
  • Patent number: 10125272
    Abstract: Thermochromic coatings, films and materials that aid in a) reducing surface temperature of a structure or composite material when environmental temperature is relatively high and b) increasing surface temperature under relatively low environmental temperature. Surface temperature modulation is achieved using a synergistic combination of thermochromic materials and light scattering components.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: November 13, 2018
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Xiong Yu, Jianying Hu
  • Patent number: 10117839
    Abstract: A composition comprising hydrophobic droplets coated by a shell and dispersed in a matrix and a consumable product comprising the composition are provided. The hydrophobic droplets comprise a hydrophobic compound, the shell comprises an irreversibly denatured protein, and the matrix comprises a protein, a starch, and a polysaccharide. Also provided are methods for preparing the composition and the consumable product.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: November 6, 2018
    Assignee: Intervet Inc.
    Inventors: Mordechai Harel, Majid Keshtmand, Swetha Kambalapally, Sara Morrison-Rowe
  • Patent number: 10111839
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 30, 2018
    Assignee: Purdue Pharma
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 10071111
    Abstract: The present invention relates to nanoemulsion type synthetic red blood cells having a calcium phosphate coating of controllable thickness, and to a preparation method thereof. According to the present invention, Ca2+ and PO42? coating layers are uniformly and sequentially formed using a layer-by-layer (LBL) coating method while controlling the thicknesses of the coating layers. Thus, the oxygen capacity and oxygen release rate of the synthetic red blood cells can be controlled, and the synthetic red blood cells can be retrieved and reused.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: September 11, 2018
    Inventor: Kyu-Bum Han
  • Patent number: 10064855
    Abstract: Provided herein are composite nanoparticles, methods of making composite nanoparticles and methods of using composite nanoparticles to treat or ameliorate various diseases, such as, for example, cancer.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: September 4, 2018
    Assignee: Los Gatos Pharmaceuticals, Inc.
    Inventors: Peter Langecker, Matthias Steiert, Toshiaki Hino, Jan Scicinksi, Kumarapandian Paulvannan
  • Patent number: 10046291
    Abstract: The present invention provides a process for producing microcapsules capable of retaining an organic compound as an active ingredient such as fragrance materials therein over a long period of time.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 14, 2018
    Assignee: KAO CORPORATION
    Inventor: Daisuke Yamazaki
  • Patent number: 10045935
    Abstract: Disclosed are gel compositions suitable for the topical administration of an active compound having poor solubility and skin penetration, for example, of a COX-2 inhibitor compounds, processes of preparation thereof and methods of use thereof for the treatment of indications treatable by the active compound.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: August 14, 2018
    Assignee: EGIS PHARMACEUTICALS PLC
    Inventors: Endre Mikulásik, Tamás Spaits, Ágota Szakályné Sinka
  • Patent number: 10029003
    Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 24, 2018
    Assignees: Mayo Foundation for Medical Education and Research, University of Leeds
    Inventors: Jose S. Pulido, Richard G. Vile, Timothy J. Kottke, Alan A. Melcher, Peter Selby
  • Patent number: 10016517
    Abstract: The present invention relates to nanoparticle compositions and treatment of cardiovascular disease using nanoparticles to target Class A and B scavenger receptors. This invention further relates to methods of detecting cells that express scavenger receptors, detecting atherosclerotic lesions, and targeting bioactive amphiphilic macromolecules to cells that express scavenger receptors.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: July 10, 2018
    Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Adam W. York, Prabhas V. Moghe, Kathryn E. Uhrich, Robert Prud'homme
  • Patent number: 10004721
    Abstract: A pharmaceutical composition comprises at least one integrase inhibitor or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug and at least one antiretroviral or anti-HIV agent or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 26, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Shrinivas Purandare
  • Patent number: 9993422
    Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: June 12, 2018
    Assignee: SpecGX LLC
    Inventors: Siva N. Raman, Jae Han Park, Thomas A. Diezi, Clifford J. Herman, Sunil K. Battu, Eric A. Burge
  • Patent number: 9981042
    Abstract: The present invention provides an anticancer agent comprising a multi-walled carbon nanotube and an anticancer drug covalently attached to the surface of the multi-walled carbon nanotube, in order to anticancer agent capable of solving drug resistance problem.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 29, 2018
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Dong Woo Khang, Sang Soo Kang, Jungil Choi, Tae Hyun Nam
  • Patent number: 9968561
    Abstract: A hard or soft capsule is disclosed comprising a shell and a fill material, wherein the shell comprises an interpenetrating network comprising a silk polymer and a film-forming natural polymer. A method of making a hard or soft capsule is also disclosed, comprising dissolving a silk protein in a solvent system to form a solubilized silk protein solution; mixing the solubilized silk protein solution with a film-forming natural polymer to form a homogenous shell material; and encapsulating a fill material with the homogenous shell material.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 15, 2018
    Assignee: Patheon Softgels Inc.
    Inventors: Tatyana Dyakonov, Derek Bush, Saujanya L. Gosangari, Yang Hue Chue, Shingai Majuru, Aqeel Fatmi
  • Patent number: 9962339
    Abstract: A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 Da), generally regarded as safe (GRAS), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time. The composition is used to deliver one or more therapeutic, prophylactic, or diagnostic agents, allowing for controlled release in response to biological stimuli such as enzymes and a greatly improved dosing efficacy.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 8, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey M. Karp, Nitin Joshi, Nikken Wiradharma, Kai Vincent Slaughter
  • Patent number: 9949987
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 24, 2018
    Assignee: Flexion Therapeutics, Inc.
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
  • Patent number: 9943608
    Abstract: In some embodiments, the present disclosure pertains to compositions for nucleic acid delivery into cells. In some embodiments, the composition comprises: (1) a cationic polymer unit comprising a plurality of polymeric arms, where the plurality of polymeric arms comprise poly(aspartic acid) derivatives; and (2) a nucleic acid associated with the cationic polymer unit. In some embodiments, the cationic polymer unit comprises a linker covalently associated with the plurality of polymeric arms. In some embodiments, the cationic polymer unit has a dendritic shape. In some embodiments, the cationic polymer unit has a star-like shape. In some embodiments, the cationic polymer unit is biodegradable. Further embodiments of the present disclosure pertain to methods of delivering a nucleic acid into cells by introducing into the cells one or more of the compositions of the present disclosure.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: April 17, 2018
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Jin Wang, Fude Feng
  • Patent number: 9938520
    Abstract: The present invention provides a cost-efficient method for producing particles having a SiO2 containing surface wherein said method comprises a) providing an aqueous reaction composition comprising i) core particles, ii) an added base, iii) a silicate salt, and iv) a pH modulator wherein the pH value of the reaction composition is above the gelation pH value; b) agitating said reaction composition, wherein the pH modulator decreases the pH value of the reaction composition over time and wherein due to said decrease of the pH value of the reaction composition SiO2 is deposited onto the core particles, whereby particles are formed which have a diameter of 30 ?m or less; and c) obtaining the particles. Furthermore, silica particles having high nucleic acid binding properties are provided.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: April 10, 2018
    Assignee: QIAGEN GmbH
    Inventor: Roland Fabis
  • Patent number: 9924733
    Abstract: The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: March 27, 2018
    Assignee: DSM IP Assets B.V.
    Inventors: Kirk E. Apt, Paul Warren Behrens, Jon Milton Hansen, Joseph W. Pfeifer, III, Tracey Lynn Stahl, Ross Zirkle
  • Patent number: 9907325
    Abstract: Disclosed are emulsions including an aqueous phase with an emulsifier dissolved in the aqueous phase, an oil phase including oil droplets, and a solid weighting agent encapsulated in the oil droplets. The ratio of the solid weighting agent to the oil phase in the emulsion may be from about 1:5 to about 1:2000. The emulsions may be used with ready-to-drink and liquid concentrate beverages. Methods for making such emulsions are also disclosed.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: March 6, 2018
    Assignee: Kraft Foods Group Brands LLC
    Inventor: Daniel T. Piorkowski
  • Patent number: 9907754
    Abstract: The invention discloses spray-dried compositions for inhalation and methods for preparing such powder compositions. The compositions of the invention are produced by spray-drying taurine under conditions that (i) retain the physical and chemical stability of the composition during spray drying and upon storage, (ii) protect the powder composition from aggregation and (iii) provide particles suitable for aerosolization.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 6, 2018
    Assignee: VECTURA LIMITED
    Inventors: David Farrow, Katie Coggins
  • Patent number: 9895318
    Abstract: The invention refers to a pharmaceutical or nutraceutical composition, comprising a) a core, comprising a pharmaceutical or a nutraceutical active ingredient, b) an inner coating layer comprising one or more salts of alginic acid and c) an outer coating layer comprising one or more water-insoluble polymers or copolymers and one or more water-soluble polymers, selected from the group of water soluble celluloses, polyvinyl pyrrolidones or polyethylene glycols or any combinations thereof. wherein the ratio by weight of the amount of the one or more salts of alginic acid in the inner coating layer to the amount of the one or more water-insoluble polymers or copolymers in outer coating layer is from 0.6 to less than 2.5:1.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: February 20, 2018
    Assignee: Evonik Roehm GmbH
    Inventors: Shraddha Sanjeev Joshi, Priyanka Parab, Harsh Shah, Preeti Patil, Smitha Shetty
  • Patent number: 9895317
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: February 20, 2018
    Assignee: Purdue Pharma L.P.
    Inventor: Richard S. Sackler
  • Patent number: 9889209
    Abstract: The present disclosure is directed to nanoconjugates that cross the blood-brain barrier and methods of their therapeutic use.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 13, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Caroline H. Ko, Alexander Stegh, David A. Giljohann, Janina Luciano, Samuel A. Jensen
  • Patent number: 9880162
    Abstract: Disclosed herein are a method for manufacturing a multi-functional bio-material conjugate used as a biosensor for detecting microorganisms, and the like, and a multi-functional bio-material conjugate manufactured by means of the same. The method for manufacturing a multi-functional bio-material conjugate includes: (a) coating a first nanoparticle having magnetic or fluorescent characteristics with protein; (b) manufacturing a conjugate by adsorbing a second nanoparticle having metallic characteristics onto the first nanoparticle coated with protein; and (c) manufacturing the multi-functional bio-material conjugate by adsorbing a bio-material onto the conjugate. The method for manufacturing a multi-functional bio-material conjugate according to the present invention may prevent precipitation of the nanoparticles, easily immobilize the bio-material, and manufacture a bio-material conjugate having multiple functions, by using two kinds of the particles.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 30, 2018
    Assignees: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Min-Gon Kim, Yun Ju Sung, Ju Young Byun, Young-Kyoung Oh, Hyou-Arm Joung
  • Patent number: 9872916
    Abstract: The present invention includes photochemical method of making hybrid metal-polymer microparticles in an aqueous, biocompatible solution by providing a metal (I) composition and one or more polymeric materials; applying an electromagnetic radiation to the metal (I) composition; converting the metal (I) composition to a metal (0) composition; forming one or more hybrid metal-polymer microparticles from the metal (0); capping the one or more hybrid metal-polymer microparticles; and stabilizing the one or more hybrid metal-polymer microparticles with the one or more polymeric materials to prevent agglomeration.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: January 23, 2018
    Assignee: University of North Texas Office of Economic Development and Technology Transfer
    Inventors: Mohammad A. Omary, Sreekar Marpu
  • Patent number: 9827254
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: November 28, 2017
    Assignee: BIOrest Ltd.
    Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
  • Patent number: 9814677
    Abstract: Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: November 14, 2017
    Assignee: MAGFORCE AG
    Inventors: Norbert Waldoefner, Kerstin Stief
  • Patent number: 9802967
    Abstract: Embodiments of the presently-disclosed subject matter include a composition that comprises a particle, a plurality of surface functional groups on a surface of the particle, and a plurality of coating polymers bound to the surface functional groups and forming a coating on the particle that includes a density ratio of about 0.1 to about 20.0, the density ratio being equal to a Flory radius of the plurality of coating polymers divided by a distance between adjacent surface functional groups. Embodiments of the presently-disclosed subject matter also include methods for making the present compositions as well as methods for using the present compositions to deliver a bioactive agent and treat a subject in need thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: October 31, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Samuel K. Lai, Qi Yang
  • Patent number: 9803184
    Abstract: The invention relates to a method for immobilizing nucleic ligands including at least one reactive amine function, by grafting on an activated solid substrate, including a step of coupling said nucleic acids on said activated solid substrate having a pH of less than 6.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: October 31, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Egisto Boschetti, Gérald Perret
  • Patent number: 9775820
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 3, 2017
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley